229 related articles for article (PubMed ID: 9511773)
1. Benign prostatic hyperplasia: use of drug therapy in primary care.
Beduschi R; Beduschi MC; Oesterling JE
Geriatrics; 1998 Mar; 53(3):24-8, 33-4, 37-40. PubMed ID: 9511773
[TBL] [Abstract][Full Text] [Related]
2. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
Kaplan SA; Olsson CA; Te AE
J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
[TBL] [Abstract][Full Text] [Related]
3. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of benign prostatic hyperplasia.
Edwards JL
Am Fam Physician; 2008 May; 77(10):1403-10. PubMed ID: 18533373
[TBL] [Abstract][Full Text] [Related]
5. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
7. Benign prostatic hyperplasia in older men.
Gerber GS
Clin Geriatr Med; 1998 May; 14(2):317-31. PubMed ID: 9536108
[TBL] [Abstract][Full Text] [Related]
8. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
9. [Current drug therapy of benign prostatic hyperplasia].
Schmidbauer CP; Madersbacher S
Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
[TBL] [Abstract][Full Text] [Related]
10. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
Barqawi AB; Myers JB; O'Donnell C; Crawford ED
BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
[TBL] [Abstract][Full Text] [Related]
11. Finasteride in benign prostatic hyperplasia.
Verhamme KM; Bosch RJ; Sturkenboom MC
N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
[No Abstract] [Full Text] [Related]
12. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
13. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
14. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
15. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
16. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
[TBL] [Abstract][Full Text] [Related]
18. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
[No Abstract] [Full Text] [Related]
19. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
20. Treatment and pharmacologic management of BPH in the context of common comorbidities.
O'Leary MP
Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]